Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging

Merck struck deals with Asia-Pacific biopharmas around a pair of clinical T cell engager programs, while two AI-guided discovery and development companies agreed to merge in a stock swap.

On Friday, Merck & Co. Inc. (NYSE:MRK) acquired from Curon Biopharmaceutical Ltd. a bispecific T cell engager targeting CD3 and CD19, paying $700 million up front. The deal includes another $600 million in developmental and regulatory milestones...